Immunohlstochemical study of COX-2 in melanocytic skin lesions

Background: cyclooxygenase-2 [cox-2] is involved in pathogenesis of various skin tumors including malignant melanoma; however, there is not enough information about cox-2 expression in benign melanocytic lesions. In the present study we compared the expression levels of cox-2 in malignant melanoma and benign melanocytic lesions

Methods: In this analytical study, 42 malignant melanoma from all 4 subtypes and 38 benign melanocytic lesions including dysplastic nevus, Spitz nevus and atypical nevus were evaluated for cox-2 expression using immunohistochemistry staining and intensity of cell staining [quantitatively and qualitatively]

Results: Malignant melanoma compared to benign melanocytic lesions had significantly higher levels of staining [p<0.00l], and much more intense coloration [p<0.00l] and higher overall staining score [p<0.001]

Regarding the cox-2 staining between malignant melanoma subtypes, all four subtypes mostly had staining intensity over 60%. Also in terms of quality, the most intense staining was in the ALM, and LM and NM had moderate staining intensity. With increasing depth of involvement, cox-2 staining increases. Intensity of cell staining was also higher in cases with tumor depth of 2-4 mm

Conclusion: The results indicate the effectiveness of cox-2 in differentiating between malignant melanoma and benign melanocytic lesions, cox-2 expression correlated with the depth of invasion. Although cox-2 alone cannot be used to differentiate melanoma from benign lesions, it can be helpful in combination with other methods, in determining the prognosis and future targeted therapies

Arterial atherosclerosis in patients with chronic kidney disease and its relationship with serum and tissue

We investigated the correlation between atherosclerosis and tissue and serum levels of endothelin-1 in patients with chronic kidney disease [CKD]. Arterial samples were obtained from 35 patients with CKD during arteriovenous fistula placement. Thirty-one patients with cardiovascular disease who underwent coronary artery bypass graft [CABG] were selected as the atherosclerotic group, and a piece of their aorta punched during CABG was obtained. Also, a small piece of the renal artery was dissected during donation in 24 kidney donors [control group]. Tissue endothelin-1 level was measured and atherosclerosis grading was determined by pathologic examination. Serum levels of endothelin-1 were also measured in the three groups. The mean tissue endothelin-1 levels were 10.73 +/- 7.57 pg/ mL, 12.16 +/- 3.95 pg/mL, and 0.93 +/- 1.06 pg/mL in the patients with CKD, those with CABG, and donors, respectively [P < .001]. The mean serum endothelin-1 level was 25.23 +/- 15.15 pg/mL in the patients with CKD, 21.13 +/- 17.22 pg/mL in the patients with CABG, and 2.66 +/- 1.51 pg/mL in the donors [P < .001]. Atherosclerosis grades correlated with tissue endothelin-1 level [r = 0.823, P < .001] and serum endothelin-1 level [r = 0.608, P < .001] in the patients with CKD. Multiple regression analysis showed tissue endothelin-1 level as the main predicting factor of atherosclerosis [P < .001]. Tissue endothelin-1 concentration is more important than serum endothelin-1 or lipids levels in prediction of atherosclerosis. Thus, blockade of tissue endothelin-1 receptors with its antagonists may prevent atherosclerosis progression